# Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia

> **NCT04374565** · PHASE2 · COMPLETED · sponsor: **University of Virginia** · enrollment: 29 (actual)

## Conditions studied

- Corona Virus Infection
- SARS-CoV 2
- SARS Pneumonia
- Pneumonia

## Interventions

- **DRUG:** High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma

## Key facts

- **NCT ID:** NCT04374565
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-05
- **Primary completion:** 2021-03-05
- **Final completion:** 2021-03-05
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2022-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04374565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04374565, "Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04374565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*